Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the Company will be participating in two upcoming conferences:

• 4^th Annual Neuroscience Innovation Forum – Norbert Riedel, Ph.D., chief executive officer, will participate in the Pain & Addiction Panel discussion at 11:30 a.m. ET on April 29, 2021; and
• 7^th Annual Truist Securities Life Sciences Summit – Aptinyx management will participate in one-on-one meetings with investors throughout the conference on May 4 – 5, 2021.

About Aptinyx

Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate—rather than block or over-activate—NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. The company has three product candidates in clinical development in central nervous system indications, including chronic pain, post-traumatic stress disorder, and cognitive impairment. Aptinyx is also advancing additional compounds from its proprietary discovery platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders. For more information, visit www.aptinyx.com.

Source: Aptinyx Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210427005080/en/